ST-segment Elevation Myocardial Infarction (STEMI) Clinical Trial
Official title:
PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction
The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).
In the STOPDAPT-2 ACS trial (NCT03462498), ischemic events (especially myocardial infarction) was significantly increased with 1-month DAPT followed by clopidogrel monotherapy, as compared to 12-month DAPT in patients with acute coronary syndrome (ACS). This was potentially attributable to clopidogrel, instead of prasugrel, which is more potent and has less individual difference in efficacy. On the other hand, previous studies including the STOPDAPT-2 ACS that evaluated the safety and efficacy of monotherapy with a P2Y12 inhibitor without aspirin consistently and significantly reduced the risk of bleeding, compared with standard DAPT. Consequently, there has been growing necessity to establish the safety with P2Y12 inhibitor monotherapy in terms of major adverse cardiovascular events. Therefore, we have planned to evaluate the non-inferiority of P2Y12 inhibitor monotherapy with prasugrel versus standard 12-month DAPT with prasugrel and aspirin in terms of the incidence of major cardiovascular events at 12 months after primary PCI in patients with STEMI using Platinum-Chromium Everolimus Eluting Stent (PtCr-EES; SYNERGYTM). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04962178 -
Evaluate Early Invasive Strategy for Patients With STEMI Presenting 24-48 Hours From Symptom Onset
|
N/A | |
| Not yet recruiting |
NCT04549766 -
Predictive Value of PRECISE DAPT Score in STEMI Patients After Primary PCI
|
||
| Not yet recruiting |
NCT05511831 -
The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI
|
Phase 4 | |
| Completed |
NCT05649696 -
Prolonged Clinical Follow-up of OPTIMA-5
|
Phase 4 | |
| Recruiting |
NCT05506449 -
The RECOVER IV Trial
|
N/A | |
| Completed |
NCT01144819 -
Platelet Inhibition in the Acute Phase of STEMI
|
N/A | |
| Recruiting |
NCT03539133 -
Systemic Organ Communication in STEMI
|
||
| Completed |
NCT01642667 -
Pharmacoinvasive Therapy With Prourokinase
|
Phase 2/Phase 3 | |
| Completed |
NCT04131816 -
HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program
|
N/A | |
| Recruiting |
NCT03768453 -
EARLY-MYO-CMR Registry
|
||
| Completed |
NCT04942977 -
Rehabilitation After Acute Coronary Syndrome: a New Telemonitoring Strategy
|
N/A | |
| Recruiting |
NCT04912518 -
Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction
|
N/A | |
| Completed |
NCT04996901 -
The Chinese STEMI PPCI Registry (CSPR)
|
||
| Recruiting |
NCT05892042 -
Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction
|
N/A | |
| Completed |
NCT02197117 -
Effect of Remote Ischemic Conditioning in Heart Attack Patients
|
N/A | |
| Completed |
NCT02733341 -
The Effect of IV Cangrelor and Oral Ticagrelor Study
|
Phase 4 | |
| Not yet recruiting |
NCT04110691 -
Impact of Stent Length and Diameter on Patients Undergoing Primary PCI
|
||
| Recruiting |
NCT05510661 -
Use of Export in Primary Percutaneous Coronary Intervention
|
N/A | |
| Recruiting |
NCT05046483 -
Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI
|
||
| Active, not recruiting |
NCT04828681 -
Angio-IMR and Cardiac MR-derived MVO in STEMI Patients
|